Importantly, the key advantage over therapies targeting EGFR signaling and those that use T cells is a much more favorable toxicity profile, with the lack of dermatologic toxicities and CRS, potentially determined by the lower proliferative potential of NK cells and macrophages and the EGFR signaling-independent mode of action of AFM24. This evidence concerns the gene EGFR and congenital rubella syndrome.